Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

Jan 30, 2025

SELL
$0.0 - $26.99 $0 - $8.1 Million
-300,000 Closed
0 $0
Q4 2022

Jan 30, 2025

BUY
$24.03 - $27.02 $7.21 Million - $8.11 Million
300,000 New
300,000 $8.09 Billion

Others Institutions Holding MYOV

About Myovant Sciences Ltd.


  • Ticker MYOV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 96,802,800
  • Description
  • Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...
More about MYOV
Track This Portfolio

Track Silphium Asset Management LTD Portfolio

Follow Silphium Asset Management LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Silphium Asset Management LTD, based on Form 13F filings with the SEC.

News

Stay updated on Silphium Asset Management LTD with notifications on news.